Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

    ... Journal Title:  Blood Primary Author:  ... cytogenetics , presence of circulating blasts, and red blood cell transfusion dependency ≥ 4 units/8 weeks (all P < 10(-4)) ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    ... Overall Response (complete or partial remission, red blood cell [RBC] or platelet transfusion independence [TI], or ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes

    ... catheter placement (ORadj=6.47, 95% CI: 2.37, 17.62) and red blood cell transfusion (ORadj=4.60, 95% CI: 2.29, 9.23) were associated ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.

    ... myelodysplastic syndromes (MDS) treated with red blood cell (RBC) transfusions. Transfusion dependency is associated with ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Myelodysplastic syndromes and the role of iron overload.

    ... in patients with MDS due to the long-term use of red blood cell transfusions in patients with symptomatic anemia . ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Iron overload in myelodysplastic syndromes: diagnosis and management.

    ... stem cell malignancies characterized by ineffective blood cell production. Many MDS patients are dependent on red blood cell (RBC) transfusions for symptomatic management of ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes

    ... Journal Title:  J Blood Med Primary Author:  ... of patients with del(5q) MDS, including reduction in red blood cell transfusion requirements and improvements in quality of ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Costs and quality of life in patients with myelodysplastic syndromes.

    ... Journal Title:  Am J Blood Res Primary Author:  ... most MDS patients become anaemic, so as to require red blood cell transfusions. To investigate the costs and the impact on ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?

    ... Erythropoiesis-stimulating agents (ESA) may reduce red blood cell transfusion requirements. MDS patients receiving ESA were ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

    ... that lenalidomide is effective not only in reducing red blood cell (RBC) transfusion burden, but also in modifying the disease ...

    Research Article last updated 07/20/2018 - 5:15pm.